Clinical Supply Chain Management – Global Pharma – Phase III

Top 20 Global Pharma Company Saves $4.95 Million in Phase III Study

A top 20 global pharma client was conducting a phase III study for a new drug product to treat Diabetes. At mid-trial, they engaged Almac's Supply Chain Management experts to devise a new optimal drug supply strategy to prevent further stock-outs. This saved the client $4.95 million per year while preventing further stock-outs.